CPT 80346 Benzodiazepine Panel Reimbursement

CPT code 80346 represents laboratory analysis for the presence or quantity of one to twelve benzodiazepines in a patient specimen. Nationally, benzodiazepine testing is important for clinical management, forensic assessment, substance use monitoring, and medication compliance programs. Accurate reporting ensures appropriate clinical follow-up and supports utilization management and payment processes.

Key payers typically participating in coverage and claims adjudication for this service include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Payer policies vary on indications, medical necessity criteria, and allowable settings, affecting prior authorization and reimbursement practices.

Readers will find: a clear clinical context for why benzodiazepine panels are ordered; the typical service setting and workflow implications for laboratories; an overview of common payer stakeholders; and where to look for policy details such as coverage criteria and billing requirements. Data not available in the input will be identified where applicable, and the publication focuses on national implications rather than state-specific rules.

Billing Code Overview

CPT code 80346 describes laboratory testing that measures the amount of, or detects the presence of, one to twelve benzodiazepines (tranquilizers) in a patient specimen. This service is a toxicology/drug detection panel focused on benzodiazepine compounds and is performed by a clinical laboratory analyst.

Service Type: Laboratory testing — qualitative and/or quantitative benzodiazepine analysis

Typical Site of Service: Clinical laboratory or hospital laboratory, including reference labs and outpatient lab draw sites.

Clinical Context

A 34-year-old adult presents to an outpatient addiction medicine clinic for monitoring of benzodiazepine use during a medication-assisted treatment program. The clinician orders a urine or serum toxicology panel specifically to detect and quantify up to twelve benzodiazepines to confirm recent use, assess for diversion, or guide tapering decisions. The specimen is collected at the clinic, labeled, and sent to the laboratory. In the lab, a clinical laboratory scientist performs analytical testing using immunoassay screening followed by confirmatory testing (e.g., gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry) as needed. Results are reported to the ordering provider; abnormal or unexpected findings may prompt clinician review of medication reconciliation, counseling, or further confirmatory testing. Typical sites of service include hospital outpatient laboratories, independent clinical laboratories, and ambulatory addiction or pain clinics offering specimen collection and send-out testing.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when reporting only the professional component for laboratory interpretation if split billing applies.
`TC`	Technical component

Taxonomy Code	Specialty	Notes
183P00000X	Pathology	Clinical pathologists supervise and interpret laboratory toxicology testing.
208000000X	Family Medicine	Primary care and addiction medicine clinicians order and interpret benzodiazepine testing as part of outpatient care.
2084P0800X	Pain Medicine	Pain management specialists order benzodiazepine testing for monitoring co-prescribed controlled substances.
213E00000X	Internal Medicine	Internists manage chronic benzodiazepine use and may order confirmatory testing.
363L00000X	Clinical Laboratory	Laboratory facility providers perform the technical testing and reporting.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F13.10`	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Indicates suspected abuse of benzodiazepines prompting toxicology testing.
`F13.20`	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Used when monitoring adherence or ongoing use in patients with benzodiazepine dependence.
`F13.21`	Sedative, hypnotic or anxiolytic dependence, in remission	May be used when monitoring for relapse during remission surveillance.
`Z79.899`	Other long term (current) drug therapy	Applied when a patient is on chronic benzodiazepine therapy requiring periodic monitoring.
`R78.89`	Other specified abnormal findings of blood chemistry	Used to report unexpected toxicology findings or abnormalities detected in laboratory testing.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80307`	Drug test, qualitative; multiple drug classes by high throughput (e.g., immunoassay), any number of classes; each procedure	Commonly used as an initial screening immunoassay for multiple drug classes prior to specific benzodiazepine quantitation or confirmation.
`80306`	Drug test, qualitative; single drug class method (e.g., immunoassay), any number of drugs in class	May be used when a single drug class screen is ordered before specific benzodiazepine confirmatory testing.
`80305`	Drug test, qualitative; non-automated, each procedure	Used for point-of-care or non-automated screening methods preceding send-out confirmatory testing.
`80346`	Drug confirmation, benzodiazepines, quantitative, one to twelve analytes	This procedure performs measurement/detection of one to twelve benzodiazepines; often performed after a positive screen.
`82542`	Assay of theophylline; multiple drug quantification examples (note: not directly benzodiazepine but analogous small-molecule quantitation)	Represents laboratory quantitative drug analysis workflows similar to benzodiazepine quantitation and may be performed in the same chemistry lab.

OpenPayer

Summary & Overview

CPT 80346: Benzodiazepine Panel — Laboratory Analysis